Sinopharm Group Co. Ltd. — Earnings Release 2024

Apr 25, 2024

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [387 x 155] intentionally omitted <==

(A joint stock limited company incorporated in the People’s Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司 ) (Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE FIRST QUARTER ENDED 31 MARCH 2024

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “ Company ”) dated 25 April 2024 (the “ Announcement ”) in relation to the report for the first quarter ended 31 March 2024 of China National Medicines Corporation Ltd. (“ SINOPHARM (CNCM LTD) ”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the first quarter ended 31 March 2024 as set out in the Announcement.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD)

Unit: Yuan Currency: RMB

	PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINSINOPHARM (CNCM LTD)	PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINSINOPHARM (CNCM LTD)	PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINSINOPHARM (CNCM LTD)	ANCIAL INDICATORS OF	ANCIAL INDICATORS OF	ANCIAL INDICATORS OF
	The ReportPerRevenue12,122,142,562Net profit attributable to shareholders of thelisted coman459,454,518				Unit: YuanCurrency: RMBhis period overiod of last year(%)7.9810.86
		RevenueNet profit attributable to shareholders of thelisted coman	The ReportPer	ingiodChanges of tthe same per	his period overiod of last year(%)
			12,122,142,562459,454,518	.33.02	7.9810.86
		pyNet profit attributable to shareholders of thelisted company after deducting non-recurringgains and losses457,982,149Net cash flow arising from operating activities-1,719,799,376Basic earnings per share (Yuan/Share)0.6Diluted earnings per share (Yuan/Share)0.6Weighted average return on equity (%)2At the end of theReporting PeriodAt the end of lyearTotal assets32,919,056,402.9532,453,092,59		.39.67089089.87astChanges ofover the2.42	11.00Not applicable10.8610.860this period-endend of last year(%)1.44
	Equity attributable to shareholdersof listed company16,229,371,972.3715,775,887,678.802.87	Equity attributable to shareholdersof listed company16,229,371,972.3715,775,887,678.802.87

Note: The Reporting Period refers to the three months ended 31 March 2024.

By order of the Board Sinopharm Group Co. Ltd. Yu Qingming Chairman

Shanghai, the PRC 25 April 2024

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the nonexecutive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.